CVRx Inc (CVRX)vsEdwards Lifesciences Corp (EW)
CVRX
CVRx Inc
$5.38
-8.50%
HEALTHCARE · Cap: $156.03M
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 10571% more annual revenue ($6.30B vs $59.07M). EW leads profitability with a 17.4% profit margin vs -89.1%. EW earns a higher WallStSmart Score of 61/100 (C+).
CVRX
Avoid29
out of 100
Grade: F
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+71.4%
Fair Value
$21.26
Current Price
$5.38
$15.88 discount
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
19.6% revenue growth
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -180.9% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : CVRX
The strongest argument for CVRX centers on Revenue Growth. Revenue growth of 19.6% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : CVRX
The primary concerns for CVRX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.03 is elevated, increasing financial risk.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
EW carries more volatility with a beta of 0.87 — expect wider price swings.
CVRX is growing revenue faster at 19.6% — sustainability is the question.
CVRX generates stronger free cash flow (-12M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EW scores higher overall (61/100 vs 29/100), backed by strong 17.4% margins and 16.7% revenue growth. CVRX offers better value entry with a 71.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CVRx Inc
HEALTHCARE · MEDICAL DEVICES · USA
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?